← Back to Search

Neuropsychological Care for Brain Metastasis

N/A
Recruiting
Led By Joshua D Palmer, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months after radiation therapy
Awards & highlights
No Placebo-Only Group

Summary

This trial is examining the effect of neuropsychological evaluation and intervention on quality of life and cognitive function in cancer patients who have received radiation therapy to the brain.

Who is the study for?
This trial is for English-speaking adults with stage IV solid tumors and brain metastases, who haven't had whole-brain radiation before. They should have a life expectancy of over 6 months. It's not for those with multiple sclerosis, Alzheimer's, dementia, or mental disabilities.
What is being tested?
The study tests if neuropsychological care by certified experts can help maintain quality of life after radiation therapy in patients with cancer that has spread to the brain. It involves assessments and questionnaires about cognitive function and well-being.
What are the potential side effects?
Since this trial focuses on evaluations rather than medications or invasive treatments, side effects are minimal but may include stress or discomfort from discussing personal health issues during assessments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months after radiation therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months after radiation therapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Quality of life (QOL)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (neuropsychological evaluation)Experimental Treatment3 Interventions
Patients undergo neuropsychological evaluations with a certified neuropsychologist at baseline, 3 months, and 6 months.
Group II: Arm II (usual care)Active Control3 Interventions
Patients receive usual care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuropsychological Assessment
2016
N/A
~60

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
294,448 Total Patients Enrolled
Joshua D Palmer, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
56 Total Patients Enrolled

Media Library

Neuropsychological Assessment Clinical Trial Eligibility Overview. Trial Name: NCT05503251 — N/A
Brain Metastasis Research Study Groups: Arm I (neuropsychological evaluation), Arm II (usual care)
Brain Metastasis Clinical Trial 2023: Neuropsychological Assessment Highlights & Side Effects. Trial Name: NCT05503251 — N/A
Neuropsychological Assessment 2023 Treatment Timeline for Medical Study. Trial Name: NCT05503251 — N/A
~2 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top